• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 10, Issue 1
  3. Author

Online ISSN: 2515-8260

Volume10, Issue1

Efficacy And Safety Of Sodium Glucose Co- Transporter 2 Inhibitors In Type 2 Diabetes Mellitus Patients

    Dr. Pushkar Mani, Dr. Anusha Vohra, Dr. Shipra Jain, Dr Chandrabhan, Dr. Ruchi Mathur

European Journal of Molecular & Clinical Medicine, 2023, Volume 10, Issue 1, Pages 3949-3956

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Type 2 Diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by hyperglycemia. It affects millions of people worldwide and is the fourth leading cause of death in India. One of the most important and effective treatment to achieve glycemic control in diabetic patients are various oral hypoglycemic agents with adequate lifestyle modifications and physical activities. Sodium glucose cotransporter 2 inhibitors are one such emerging oral hypoglycemic agents that achieve the desired goal with some complimentary benefits. This prospective observational study using four different SGLT2 inhibitors amongst 68 patients with Type II diabetes namely Canagliflozin 100 mg, Dapagliflozin 10 mg, Empagliflozin 25 mg, Remogliflozin 100mg has shown promising results in managing glycemic control along with complimentary benefits including weight loss
Keywords:
    SGLT2inhibitors Diabetes Kidney disease Canagliflozin Empagliflozin Remogliflozin Dapagliflozin Glycated hemoglobin
  • PDF (222 K)
  • XML
(2023). Efficacy And Safety Of Sodium Glucose Co- Transporter 2 Inhibitors In Type 2 Diabetes Mellitus Patients. European Journal of Molecular & Clinical Medicine, 10(1), 3949-3956.
Dr. Pushkar Mani, Dr. Anusha Vohra, Dr. Shipra Jain, Dr Chandrabhan, Dr. Ruchi Mathur. "Efficacy And Safety Of Sodium Glucose Co- Transporter 2 Inhibitors In Type 2 Diabetes Mellitus Patients". European Journal of Molecular & Clinical Medicine, 10, 1, 2023, 3949-3956.
(2023). 'Efficacy And Safety Of Sodium Glucose Co- Transporter 2 Inhibitors In Type 2 Diabetes Mellitus Patients', European Journal of Molecular & Clinical Medicine, 10(1), pp. 3949-3956.
Efficacy And Safety Of Sodium Glucose Co- Transporter 2 Inhibitors In Type 2 Diabetes Mellitus Patients. European Journal of Molecular & Clinical Medicine, 2023; 10(1): 3949-3956.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 22
  • PDF Download: 10
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus